Published in JAMA Neurol on February 01, 2013
A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol (2016) 2.86
Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol (2014) 2.37
Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry (2013) 2.33
Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol Neuroinflamm (2015) 1.19
Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity. J Neurol (2014) 1.02
Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies. Neurotherapeutics (2016) 1.02
Clinical spectrum and diagnostic value of antibodies against the potassium channel related protein complex. Neurologia (2014) 0.97
The clinical spectrum of Caspr2 antibody-associated disease. Neurology (2016) 0.97
An 11-year retrospective experience of antibodies against the voltage-gated potassium channel (VGKC) complex from a tertiary neurological centre. J Neurol (2014) 0.95
Clinical relevance of voltage-gated potassium channel–complex antibodies in children. Neurology (2015) 0.85
Acquired neuromyotonia heralding recurrent thymoma in myasthenia gravis. JAMA Neurol (2013) 0.83
The neurologic significance of celiac disease biomarkers. Neurology (2014) 0.83
Hemichorea Associated with CASPR2 Antibody. Tremor Other Hyperkinet Mov (N Y) (2014) 0.83
Limbic Encephalitis: Potential Impact of Adaptive Autoimmune Inflammation on Neuronal Circuits of the Amygdala. Front Neurol (2015) 0.82
[(18)F]-Fluoro-Deoxy-Glucose Positron Emission Tomography Scan Should Be Obtained Early in Cases of Autoimmune Encephalitis. Autoimmune Dis (2016) 0.80
Clinical utility of seropositive voltage-gated potassium channel-complex antibody. Neurol Clin Pract (2016) 0.79
Copy number variations in a population-based study of Charcot-Marie-Tooth disease. Biomed Res Int (2015) 0.79
Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions. J Neurol (2014) 0.78
A Chinese female Morvan patient with LGI1 and CASPR2 antibodies: a case report. BMC Neurol (2016) 0.77
Seizures and Epilepsies due to Channelopathies and Neurotransmitter Receptor Dysfunction: A Parallel between Genetic and Immune Aspects. Mol Syndromol (2016) 0.76
P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments. Muscle Nerve (2016) 0.75
Eyelid tremor in a patient with anti-caspr2 antibody-related encephalitis. Case Rep Neurol (2014) 0.75
Sensorimotor polyneuropathy and foot-drop as result of a prostate cancer paraneoplastic syndrome. Res Rep Urol (2013) 0.75
Commentary. J Neurosci Rural Pract (2016) 0.75
Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. Neurology (2017) 0.75
Neuronal central nervous system syndromes probably mediated by autoantibodies. Eur J Neurosci (2016) 0.75
Advances in Autoimmune Epilepsy Associated with Antibodies, Their Potential Pathogenic Molecular Mechanisms, and Current Recommended Immunotherapies. Front Immunol (2017) 0.75
Innate and adaptive immunity in human epilepsies. Epilepsia (2017) 0.75
Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol (2010) 7.97
Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol (2011) 2.99
Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol (2004) 2.91
Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol (2008) 2.80
Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol (1995) 2.79
Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol (2012) 2.49
Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol (1997) 2.17
Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain (2001) 2.14
Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc (2010) 1.85
Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol (2011) 1.77
Potassium channel antibody associated encephalopathy presenting with a frontotemporal dementia like syndrome. Arch Neurol (2007) 1.48
Neurophysiologic studies in Morvan syndrome. J Clin Neurophysiol (2004) 1.30
Eliminating false-positive results in serum tests for neuromuscular autoimmunity. Muscle Nerve (2010) 1.00
Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology (2009) 0.92
Psychiatric manifestations of voltage-gated potassium-channel complex autoimmunity. J Neuropsychiatry Clin Neurosci (2011) 0.90
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain (2010) 4.77
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc (2007) 3.32
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol (2012) 2.95
Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol (2004) 2.91
Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol (2008) 2.80
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc (2013) 2.64
Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol (2012) 2.49
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol (2003) 2.29
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol (2010) 2.26
Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A (2011) 2.11
Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol (2013) 2.10
Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc (2003) 2.09
Experimental autoimmune autonomic neuropathy. J Neurophysiol (2003) 2.02
Do not treat from CIS onset: evaluate disease course and prognosis first--yes. Mult Scler (2012) 2.01
Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology (2012) 2.00
The spectrum of autoimmune autonomic neuropathies. Ann Neurol (2003) 1.93
Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc (2010) 1.85
Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol (2003) 1.79
Passive transfer of autoimmune autonomic neuropathy to mice. J Neurosci (2004) 1.78
Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol (2011) 1.77
An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. Lancet Neurol (2009) 1.73
Autoimmune encephalopathies and epilepsies in children and teenagers. Can J Neurol Sci (2012) 1.62
Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol (2009) 1.61
Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol (2010) 1.60
Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol (2008) 1.59
Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol (2009) 1.55
Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol (2005) 1.51
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images. Arch Neurol (2009) 1.48
Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc (2006) 1.46
Striational antibodies in a paraneoplastic context. Muscle Nerve (2013) 1.46
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry (2012) 1.42
CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology (2011) 1.41
Pseudopseudoseizures: conditions that may mimic psychogenic non-epileptic seizures. Psychosomatics (2011) 1.39
Neuromyelitis optica: changing concepts. J Neuroimmunol (2007) 1.39
Idiopathic autonomic neuropathy: comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. Arch Neurol (2004) 1.38
Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol (2002) 1.36
Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol (2012) 1.34
Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res (2004) 1.33
Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol (2010) 1.28
GABAB receptor autoantibody frequency in service serologic evaluation. Neurology (2013) 1.28
Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine. Gastroenterology (2006) 1.28
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol (2009) 1.27
Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clin Gastroenterol Hepatol (2008) 1.17
Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. J Autoimmun (2012) 1.16
NMO-IgG: a specific biomarker for neuromyelitis optica. Dis Markers (2006) 1.14
Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve (2002) 1.13
Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve (2009) 1.13